Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genvoya vs EFV-TDF-3TC for Same-Day ART Initiation
NCT03405194Withdrawn
- Sponsor
- GHESKIO
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GHESKIO. Primary endpoint: 48-week viral suppression. Planned start May 2018; status: withdrawn.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03405194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405194.